Patient Square Capital’s Cullinan Oncology CGEM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-868,897
Closed -$6.54M 25
2025
Q2
$6.54M Sell
868,897
-10,000
-1% -$80.4K 2.36% 7
2025
Q1
$6.65M Hold
878,897
2.75% 6
2024
Q4
$10.7M Buy
878,897
+54,192
+7% +$779K 4% 4
2024
Q3
$13.8M Buy
+824,705
New +$14.6M 5.12% 3

Other funds holding CGEM

Patient Square Capital's CGEM Position: Q3 2025 in Review

Patient Square Capital sold out of Cullinan Oncology (CGEM) in Q3 2025, closing a stake of 868,897 shares — an estimated $6.54M sold.

Patient Square Capital first reported a position in CGEM in Q3 2024 and held it in 4 quarters. The position peaked at $13.8M in Q3 2024. 145 funds tracked by Wall St. Rank hold CGEM as of Q3 2025.

  • Patient Square Capital reported no remaining Cullinan Oncology position as of Q3 2025 after selling out during the quarter.
  • Patient Square Capital sold 868,897 Cullinan Oncology shares in Q3 2025, an estimated $6.54M.
  • Patient Square Capital first reported a position in Cullinan Oncology in Q3 2024 and held it in 4 quarters.
  • Patient Square Capital's Cullinan Oncology position peaked at $13.8M in Q3 2024.
  • 145 funds tracked by Wall St. Rank held Cullinan Oncology as of Q3 2025.

Based on Patient Square Capital's 13F filing for Q3 2025, filed 10 Nov 2025.